Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00017550 · ClinicalTrials.gov registry record · Phase 2
Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome
A Phase 2 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00017550 is a Phase 2 study that has completed, run by Genzyme, a Sanofi Company.
The verdict
NCT00017550, a Phase 2 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Immunosuppressive therapy may improve bone marrow abnormalities and may be effective treatment for myelodysplastic syndrome. It is not yet known whether immunosuppressive therapy is more effective than supportive care in treating myelodysplastic syndrome. PURPOSE: Randomized phase II trial to compare the effectiveness of antithymocyte globulin with that of supportive care in treating patients who have myelodysplastic syndrome.
Interventions
- BIOLOGICAL anti-thymocyte globulin
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-09 |
| Est. Completion | 2003-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00017550
The ClinicalTrials.gov registry entry for NCT00017550 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which anti-thymocyte globulin is the first listed.
NCT00017550 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00017550 about?
NCT00017550 is a clinical study titled "Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome". RATIONALE: Immunosuppressive therapy may improve bone marrow abnormalities and may be effective treatment for myelodysplastic syndrome. It is not yet known whether immunosuppressive therapy is more effective than supportive care in treating myelodysplastic syndrome. PURPOSE: Randomized phase II tri...
What is the current status of trial NCT00017550?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-09. Estimated completion is 2003-11.
What interventions are being tested in trial NCT00017550?
The interventions under investigation include: anti-thymocyte globulin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00017550?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.